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Some labile cell types whose numbers are normally
controlled through programmed cell death are subject to
markedly increased destruction during some severe infec-
tions. Lymphocytes, in particular, undergo massive and
apparently unregulated apoptosis in human patients and
laboratory animals with sepsis, potentially playing a major
role in the severe immunosuppression that characterizes
the terminal phase of fatal illness. Extensive lymphocyte
apoptosis has also occurred in humans and animals infect-
ed with several exotic agents, including Bacillus anthracis,
the cause of anthrax; Yersinia pestis, the cause of plague;
and Ebola virus. Prevention of lymphocyte apoptosis,
through either genetic modification of the host or treatment
with specific inhibitors, markedly improves survival in
murine sepsis models. These findings suggest that inter-
ventions aimed at reducing the extent of immune cell apop-
tosis could improve outcomes for a variety of severe
human infections, including those caused by emerging
pathogens and bioterrorism agents.
D
espite success in controlling many infectious dis-
eases, efforts to defend against the wide range of
microbes that threaten human health continue to be chal-
lenged by the unexpected emergence of novel pathogens
and possible use of a variety of virulent agents as bio-
logical weapons. A defensive strategy based solely on
developing new vaccines and antimicrobial and antiviral
drugs, each specific for only 1 or a few agents, is unlikely
to be successful in dealing with potential microbial threats
and will be exceedingly expensive. An alternative
approach attempts to identify mechanisms shared by most
or all severe infections that could be targets for pharmaco-
logic intervention. Such generic therapies could supple-
ment agent-specific treatment by increasing resistance to
infection, potentially improving outcomes for patients in a
variety of disease states.
One physiologic process that characterizes some
severe infections is a massive loss of lymphocytes, den-
dritic cells, gastrointestial epithelial cells, and other cell
types through apoptosis, or programmed cell death. This
process is an apparent acceleration or dysregulation of the
same process by which these cell populations are regulat-
ed during normal health (1,2). By impairing the develop-
ment of adaptive immune responses needed for recovery,
the apoptotic destruction of lymphocytes and dendritic
cells could have a particularly adverse effect on disease
outcome. Fortunately, because programmed cell death is
an orderly biochemical process triggered by specific stim-
uli and executed by a limited range of enzymes, it could be
inhibited through pharmacologic countermeasures, offer-
ing a novel approach to therapy.
We begin this article by summarizing evidence that a
massive apoptotic loss of lymphocytes takes place in
humans during the course of septic shock and describing
similar findings in animal models of sepsis. Data are then
presented that indicate that a marked die-off of lympho-
cytes also occurs in Ebola hemorrhagic fever, anthrax, and
plague, which suggests that unregulated apoptosis of these
cells is a component of many, and perhaps all, severe
infectious processes and may contribute to high case fatal-
ity rates by impairing adaptive immune function. After
describing encouraging results obtained in proof-of-con-
cept tests of antiapoptotic interventions in lethal murine
models of sepsis, we note some potential limitations of
such therapy that could slow its introduction into the
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USAtherapeutic regimen. Whatever the potential role of such
strategies, improved understanding of the causes, time
course, and extent of programmed cell death will aid man-
agement of patients with severe infections.
Mechanism and Regulation of Apoptosis
Apoptosis, or programmed cell death, is the method
by which tissue remodeling takes place during normal
growth and development and the physiologic mechanism
by which labile cell populations such as gastrointestinal
epithelial cells, lymphocytes, dendritic cells, and neu-
trophils are regulated. Apoptosis is of particular impor-
tance for the immune system as the means by which
self-recognizing lymphocytes are deleted and expanded
lymphocyte populations are reduced at the conclusion of
an acute immune response (3). This closely regulated,
energy-requiring process can be initiated through 2 differ-
ent mechanisms, each based on the successive activation
of preexisting but dormant cysteine-aspartate proteases, or
caspases (Figure 1).
As its name implies, the intrinsic apoptotic pathway
begins within the cell, when toxic alterations bring about a
decrease in mitochondrial transmembrane potential, lead-
ing to the opening of mitochondrial membrane pores and
the release of cytochrome C and other substances into the
cytoplasm. The extrinsic pathway, by contrast, is triggered
by extracellular events through the binding to cell surface
receptors of tumor necrosis factor (TNF) superfamily
death ligands, including TNF-α and Fas ligand. Although
the intrinsic pathway involves early activation of caspase-
9, and the extrinsic pathway is mediated through caspase-
8, both lead to activation of the “executioner” caspase-3
and a variety of proteases and endonucleases. Once begun,
apoptosis may be described as an orderly disassembly of
the cell from within. Chromosomal DNA is cleaved into
oligonucleosomal segments, the nucleus is divided into
discrete subunits, and the cell itself is partitioned into mul-
tiple membrane-bound fragments whose outer surfaces are
marked by large numbers of phosphatidylserine molecules,
leading to their rapid uptake by phagocytes. Because all
multicellular organisms use programmed cell death to
maintain and modify their tissues, this process does not
evoke an inflammatory response, and its end products
actually serve as antiinflammatory stimuli. Apoptosis thus
differs markedly from necrosis, the chaotic breakdown
resulting from trauma and other types of damage, in its
morphologic and immunologic features (Table 1).
Necrosis is characterized by the early loss of outer mem-
brane function, rapid cytoplasmic swelling and disintegra-
tion, and release of cell contents into surrounding tissues,
which evoke an intense inflammatory response.
A large number of cell-surface and cytoplasmic pro-
teins participate in the detection and processing of signals
that tip the balance toward or away from programmed cell
death. These include members of the Bcl-2 protein family,
which have both proapoptotic and antiapoptotic activity
(Bcl-2 is antiapoptotic), and other inhibitors (Figure 1).
Despite these elaborate control mechanisms, innate or
acquired defects in the control of apoptosis may lead to a
variety of disease states. For example, excessive inhibition
of apoptosis is an underlying mechanism of cancer, while
an inappropriate increase is seen in some neurodegenera-
tive diseases and other conditions.
Lymphocyte Apoptosis in Sepsis
During normal health, the immediate fate of each lym-
phocyte is determined through continuous summation of a
stream of proapoptotic and antiapoptotic signals that arrive
from its external environment and from its internal cyto-
plasmic milieu. A shift toward initiation of apoptosis
should therefore be expected during the early phase of sep-
sis, when bacteria or their byproducts stimulate
macrophages to release proapoptotic substances such as
TNF-α, nitric oxide, and glucocorticoids. As the disease
develops, accumulating products of lymphocyte apoptosis
can act as antiinflammatory stimuli, which contribute
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Figure 1. Apoptotic pathways of cell death. The extrinsic pathway
is mediated by a variety of death receptor ligands, including tumor
necrosis factor (TNF) and Fas ligand (FasL), that trigger apoptosis
by binding to cell surface receptors. In the intrinsic pathway, sev-
eral adverse factors act upon mitochondria to cause loss of the
mitochondrial membrane potential, resulting in leakage into the
cytosol of cytochrome C (Cyto C), which together with apoptotic
protease activating factor 1 forms the apoptosome that activates
caspase-9. Communication between the pathways exists through
cleavage of Bcl-2 interacting domain (Bid) by active caspase-8 to
form truncated Bid (tBid). Inhibitors of apoptosis (IAPs) can pre-
vent caspase activation under certain conditions. Trail, tumor
necrosis factor-α–related apoptosis-inducing ligand; Bim/Puma,
Bcl-2 interacting mediator of cell death/p53-upregulated modulator
of apoptosis; FADD, Fas-associated death domain; FLIP, Fas-
associated death domain-like interleukin-1  converting enzyme-
like inhibitory protein.to the immunosuppression commonly observed as sepsis
progresses to septic shock, and which can lead to a state of
immune paralysis before death (2,3).
Numerous studies have demonstrated a massive apop-
totic loss of lymphocytes during sepsis. A prospective
investigation in adult patients compared spleens obtained
either intraoperatively or within 6 hours after death from
sepsis or trauma and found that those from sepsis patients
showed a marked decrease in B cells and CD4 T cells
(Figure 2) (1). The degree of splenic B-cell depletion cor-
responded with the duration of sepsis. Active caspase-9
was present in splenic lymphocytes with apoptotic fea-
tures, suggesting a mitochondrial-mediated pathway of
cell death, although evidence indicates that apoptotic cell
death in patients with sepsis can also proceed by the death
receptor pathway (4). In most patients, loss of cells from
the spleen corresponded with a premortem decrease in cir-
culating lymphocytes.
These findings were closely paralleled in another
postmortem study, which showed that B and T cells and
dendritic cells were markedly depleted in lymphoid organs
of children dying of sepsis and that >3% of cells exhibit-
ed histologic signs of apopotosis (5). Approximately 15%
of patients had prolonged lymphopenia during their termi-
nal course. This report suggested a possible stimulus for
apoptosis, in the form of persistent hypoprolactinemia,
because prolactin up-regulates expression of the antiapop-
totic protein Bcl-2. A third study also noted a profound
loss of B and T cells in the spleens of neonates who died
of sepsis and chorioamnionitis. Another study compared
premortem blood counts in patients with septic shock, sep-
sis without shock, or nonseptic critical illness and found
that increased lymphocyte apoptosis began early in septic
shock, and that severe lymphopenia was predictive of a
fatal outcome (6,7).
Extensive loss of lymphocytes through programmed
cell death has also been demonstrated in animal models of
lethal sepsis induced either by normal intestinal flora or by
specific gram-negative bacteria. Studies using cecal liga-
tion and perforation (CLP) in mice have shown profound
lymphocyte apoptosis in multiple organs, including the
thymus and spleen (8). Massive lymphoid apoptosis in the
spleen and lymph nodes was also observed in baboons that
developed fatal septic shock after injection of Escherichia
coli (9).
Lymphocyte Apoptosis in Ebola 
Hemorrhagic Fever
In addition to occurring during common forms of sep-
sis, a marked increase in lymphocyte apoptosis has been
observed in such exotic illnesses as Ebola hemorrhagic
fever. When transferred to humans from an unidentified
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Figure 2. Immunohistochemical identification
of B cells and follicular dendritic cells in
spleens of patients dying of trauma or sepsis.
Total B cells are decreased in the spleen of a
patient with sepsis (B) compared with that of
a trauma patient (A) (magnification ×400).
Similarly, follicular dendritic cells are
decreased in the spleen of a patient with sep-
sis (D) compared with that of a trauma patient
(C) (magnification ×600).animal reservoir, Ebola virus replicates rapidly in
macrophages and dendritic cells, causing intense inflam-
mation, high viremia, and spread of infection to multiple
organs, with fever, coagulation abnormalities, and shock
(10). Case fatality rates have reached 90% in outbreaks in
central Africa.
Limited data from patients and more extensive data
from laboratory animals indicate that massive lymphocyte
apoptosis occurs during Ebola hemorrhagic fever and may
contribute to the high death rate. Thus, the few patients
who survive infection develop antibodies to the virus dur-
ing the second week of illness, while fatally infected per-
sons apparently undergo terminal immunosuppression
similar to that seen with septic shock (11,12). A small
study of blood samples from patients in Gabon showed
that fatal cases of Ebola hemorrhagic fever were character-
ized by extensive intravascular apoptosis, particularly of T
cells, beginning at least 5 days before death, with a
decrease and eventual disappearance of Bcl-2 mRNA
expression (11). In survivors, by contrast, Bcl-2 mRNA
was identified in circulating cells during T-cell activation.
Importantly, a similar loss of Bcl-2 has been reported in
circulating lymphocytes of patients with sepsis (4).
Because of the difficulty of performing clinical
research under the conditions of an Ebola outbreak, the
pathogenesis of lethal infection has been elucidated princi-
pally through intensive studies in nonhuman primates,
which develop uniformly lethal illness resembling fatal
hemorrhagic fever in humans. Lymphocytes in these ani-
mals remain free of viral infection but nevertheless under-
go extensive apoptosis, with early development of
lymphopenia and depletion of circulating natural killer
cells and CD4+ and CD8+ lymphocytes (13). Massive
lymphocyte apoptosis is also observed histologically in
lymph nodes, spleen, and other lymphoid tissues, begin-
ning by day 3 postinfection. A model of Ebola virus infec-
tion in mice has demonstrated extensive lymphocytolysis
in lymph nodes, spleen, and thymus, with histologic fea-
tures suggestive of apoptosis (14). Lymphocyte apoptosis
has also been demonstrated in vitro in cultures of Ebola
virus–infected peripheral blood mononuclear cells, which
suggests that infected monocytes release substances that
induce apoptosis in neighboring lymphocytes (15).
Lymphocyte Apoptosis in Anthrax
In inhalational anthrax, spores of Bacillus anthracis
are carried by pulmonary macrophages to mediastinal
lymph nodes, where their replication results in local tissue
injury, bacteremia, shock, and death (16). The ability of the
organism to cause rapidly overwhelming infection sug-
gests that, as in the case of Ebola hemorrhagic fever,
immunosuppression plays a role in lethal illness. Few data
are available from human cases to assess whether acceler-
ated lymphocyte apoptosis contributes to this process, but
a review of autopsy findings from 41 known cases of
inhalational anthrax in a 1979 outbreak in Sverdlorsk,
Russia, showed massive lymphocytolysis in mediastinal
lymph nodes and spleens that was morphologically consis-
tent with apoptosis (17).
Experimental evidence shows that lethal toxin (LT),
an important virulence factor encoded by B.  anthracis,
interferes with intracellular signaling and can induce apop-
tosis. Ultrastructural analysis and terminal deoxynu-
cleotidyl (TUNEL) staining of LT-treated human
monocyte–derived dendritic cells found activation of
apoptotic pathways (18). The same authors demonstrated
that bone marrow dendritic cells from C57BL/6 and
BALB/c mice differed in susceptibility to LT: cells derived
from C57BL/6 mice underwent apoptosis and LT caused
necrosis of equivalent cells from BALB/c mice.
Lymphocyte Apoptosis in Plague
The gram-negative bacillus Yersinia pestis causes 2
principal forms of illness in humans, a localized infection
of lymph nodes (bubonic plague) and a highly lethal sep-
ticemia that is a particularly fulminant form of septic shock
(19). The striking virulence of Y. pestis in humans is attrib-
utable to a collection of outer membrane proteins (Yops)
that cause immune suppression and trigger apoptosis (20).
Patients dying of plague would therefore be expected to
demonstrate increased lymphocyte apoptosis, but data to
support this hypothesis are lacking. However, laboratory
studies using a murine model of intranasal Y. pestis infec-
tion have provided evidence of increased lymphocyte
apoptosis in the spleen by 36 hours after infection (21) (R
Hotchkiss, V. Miller, unpub. data).
YopH protein inhibits T cell activation by blocking
early phosphorylation events necessary for signal trans-
duction through the antigen receptor (22). In tests with pri-
mary T cells or Jurkat T leukemia cells, the extended
presence of YopH led to apoptosis through a mitochondria-
dependent pathway, as indicated by mitochondrial break-
down, caspase activation, DNA fragmentation, and
annexin V binding. Cell death could be blocked through
coexpression of Bcl-xL, an antiapoptotic protein in the Bcl-
2 family, or by treatment with caspase inhibitors. Evidence
of induction of apoptosis was also found in a plague model
in rats, in which increased numbers of caspase-positive
cells were noted in lymph nodes 36 hours after infection,
most prominently in nodes containing the greatest number
of bacteria, which suggests Yop-mediated apoptosis (23).
However, the apoptotic cells could not be identified
because of extensive tissue destruction. Multifocal lym-
phocytolysis was also observed in the white pulp of the
spleen, with resultant loss of periarteriolar lymphoid
sheath–associated lymphocytes.
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Efforts to prevent excessive lymphocyte apoptosis
during severe infection have focused either on modifica-
tion of the signal processing system to create an inherent
bias against the triggering of cell death pathways or on
inhibition of caspase activity to block their execution.
Proof-of-concept experiments with murine sepsis models
have shown that both approaches can improve survival.
Several studies have shown that transgenic mice overex-
pressing the antiapoptotic protein Bcl-2 were completely
protected against lymphocyte apoptosis in T cells and par-
tially protected in B cells after CLP and showed an
increase in survival (24,25). The exact protective mecha-
nisms, however, are unclear. The authors of 1 report
argued that the beneficial effect of Bcl-2 did not depend
on prevention of lymphocyte apoptosis because adoptive
transfer of myeloid cells overexpressing Bcl-2 also result-
ed in improved survival after CLP of Rag-1−/− mice,
which lack mature T and B cells (25). This finding sug-
gests that protection resulted from the release of cytopro-
tective or antiinflammatory molecules from Bcl-2-
overexpressing cells, from an increase in neutrophils at
sites of infection, or both. Despite these findings, recent
studies that showed a lower death rate after CLP in trans-
genic mice expressing the antiapoptotic protein Akt in T
cells have added further support to the concept that pre-
vention of lymphocyte apoptosis is an independent sur-
vival factor in sepsis (26).
In addition to these reports that used the CLP model,
preliminary studies have shown that Bcl-2 overexpression
prevents lymphocyte apoptosis in mice infected with Y.
pestis (R. Hotchkiss, unpub. data). Bcl-2 transgenic mice
that overexpressed Bcl-2 in T and B lymphocytes had a
marked decrease in apoptosis at 72 hours after Y. pestis
infection compared with wild-type animals (Figure 3).
These findings provide hope that apoptotic cell death in
plague may be preventable by a Bcl-2–based   therapy.
Pharmacologic interventions have also been used to
prevent initiation of lymphocyte apoptosis in murine mod-
els of sepsis (Table 2). One approach has aimed to block
initial triggering of the extrinsic pathway by preventing
cellular synthesis of Fas or FasL or by administering an
inhibitor of Fas-FasL binding. Both techniques have
shown benefit in murine CLP studies. Preliminary studies
by Chung et al. demonstrated that mice genetically defi-
cient in FasL showed better survival after CLP than their
wild-type counterparts (34), and a survival benefit was
also observed when mice were treated with siRNAto block
intracellular synthesis of Fas (28). Markedly improved sur-
vival was also observed when a Fas receptor fusion protein
was injected subcutaneously 12 hours after CLP to act as a
decoy for FasL binding. Detailed studies have shown that
this intervention restores normal immune function,
improves cardiac output, and lowers the serum level of the
antiinflammatory cytokine interleukin-10 (27).
Another strategy aims to influence intracellular sig-
naling networks in a direction opposing the initiation of
programmed cell death. A recent publication by the
Hotckhiss group showed that this could be achieved by
exploiting the normal CD40 regulatory pathway through
which lymphocytes are stimulated in an antiapoptotic
direction to produce clonal expansion and functional mat-
uration (30). Mice treated with a monoclonal antibody that
binds to and stimulates the CD40 receptor showed up-reg-
ulation of the antiapoptotic protein Bcl-xL, an absence of
apoptosis of B cells, a decrease in loss of T cells, and a
resistance to CLP (29).
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Figure 3. Decreased apoptosis caused by overexpression of Bcl-2
protein in a mouse model of plague. Wild-type mice (A) and mice
that overexpressed Bcl-2 in lymphocytes (B) were injected
intranasally with Yersinia pestis. Thymuses were obtained at 72 h
postinfection and stained by using the terminal deoxynucleotidyl
(TUNEL) method as a marker of apoptotic cell death. Note the
decrease in apoptotic cells in the thymus of the Bcl-2 transgenic
mouse (magnification ×400).Efforts have also been made to alter intracellular sig-
naling by introducing active portions of Bcl-xL fused to
carrier peptides to facilitate its transport into cells. In a
murine CLP model, treatment resulted in a decrease in
lymphocyte apoptosis, but the effect was less marked than
that observed in transgenic animals constitutively express-
ing the same protein (30). Another approach has used the
licensed HIV protease inhibitors nelfinavir and ritonavir,
which in addition to blocking the cleavage of HIV propep-
tides have direct antiapoptotic effects (31). The latter were
initially assumed to result from caspase inhibition, but fur-
ther studies showed that these drugs prevent initiation of
the intrinsic apoptotic pathway by stabilizing the mito-
chondrial membrane potential. Oral administration of nel-
finavir and ritonavir to mice, beginning either before or 4
hours after CLP, resulted in decreased lymphocyte apopto-
sis and improved survival (31). Because both drugs are
licensed for use in humans, this approach could potential-
ly be evaluated in sepsis patients.
Efforts to prevent completion of the programmed cell
death process by blocking executioner caspases have also
been reported. Studies with the broad-spectrum caspase
inhibitor zVAD showed decreased apoptosis and improved
survival in a mouse CLP model (32). Similarly, a selective
caspase-3 inhibitor decreased blood bacterial counts and
improved survival in mice with sepsis (33). Treatment of
septic Rag 1−/− mice with caspase inhibitors failed to
improve survival, which suggests that the beneficial effect
required the presence of lymphocytes.
Potential Limitations of Antiapoptotic Therapy
Although the proof-of-concept studies described
above have shown promising results, deliberate inhibition
of apoptosis during severe infections might have unexpect-
ed and undesired consequences. One potential adverse
effect of antiapoptotic therapy involves its effects on
pathogen replication. Some intracellular agents, such as
poxviruses, actively inhibit apoptosis of their host cells so
as to permit their own continued replication. Theoretically,
pharmacologic inhibition of apoptosis in those situations
could actually worsen the clinical outcome by providing an
advantage to the pathogen. It may therefore be essential to
identify the causative agent of infection before initiating
antiapoptotic therapy. An alternative approach that may
offer several advantages is targeted delivery of antiapop-
totic molecules. Similar to current immune-based thera-
pies, apoptosis inhibitors could be directed to specific
classes of immune cells, for example by conjugating them
to antibodies to CD4 or CD20, thus avoiding adverse con-
sequences (35).
Other potential limitations of antiapoptotic therapy
relate to possible undesired effects of the use of caspase
inhibitors. First, because only a small amount of activated
caspase-3 is sufficient to initiate genomic DNAbreakdown
and lead to apoptotic cell death, a high degree of inhibition
would be needed to achieve therapeutic effectiveness (36).
This requirement presents a therapeutic challenge because
of the need for persistent and nearly complete caspase
blockade. In addition, there is increasing recognition that
caspases have numerous functions in addition to their roles
as mediators of programmed cell death. One subset of cas-
pases is critical for regulation of inflammation by process-
ing proinflammatory cytokines such as interleukin-1β;
others are essential for lymphocyte activation, prolifera-
tion, and protective immunity (37,38). Patients with
defects in caspase-8, for example, are immunodeficient
and have recurring infections (39). Blocking caspases
might therefore have some beneficial effects in decreasing
lymphocyte apoptosis in sepsis, but these could be coun-
terbalanced by adverse effects on the ability of the patient
to mount an effective immune response. Finally, that inhi-
bition of caspases might induce hyperacute TNF-induced
shock in certain situations has been recently reported (40).
In view of the possible deleterious effects of using caspase
inhibitors to treat sepsis, therapy directed at a temporary
inhibition of specific caspases, such as caspase-3 or cas-
pase-12, timed to either the hyperinflammatory phase or
the hypoinflammatory phase of sepsis, might be the most
effective approach.
Conclusions
Amassive loss of lymphocytes and other cells through
apoptosis is a proven component of the physiologic
changes that occur over the course of septic shock. This
process appears also to occur in a variety of other severe
infections, including anthrax, plague, and Ebola hemor-
rhagic fever, which are of major concern for biodefense. A
variety of proof-of-concept studies with murine sepsis
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worsens disease outcome because its prevention through
genetic modification or pharmacologic intervention
improves survival. Research is needed to assess the possi-
ble contribution of lymphocyte apoptosis to immune
impairment in other disease processes, including a variety
of newly emerging infections. By helping to bolster
immune function, the development of antiapoptotic thera-
pies could mitigate the consequences of infection by a
wide variety of pathogenic agents.
Dr Parrino is a clinical fellow in allergy and immunology at
the National Institute of Allergy and Infectious Diseases. Her
research interests include protocols focusing on new vaccines,
emerging infectious diseases, and biodefense.
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